Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SummaryBackground  Delivering drugs in a fixed combination is essential to the success of the strategy of artemisinin‐based combination therapy. This prevents one drug being taken without the protection of the other, reducing the chance of emergence and spread of drug resistant strains of Plasmodium falciparum. A lower tablet burden should also facilitate adherence to treatment. A new fixed combination of mefloquine plus artesunate has been developed. This was compared with the conventional regimen of separate tablets for the treatment of uncomplicated multidrug‐resistant falciparum malaria.Methods  On the north‐western border of Thailand 500 adults and children with uncomplicated falciparum malaria were randomized to receive either the new fixed combination or separate tablets. They were followed up weekly for 63 days.Results  The day 63 polymerase chain reaction‐adjusted cure rates were 91.9% (95% CI 88.2–95.6) in the fixed combination group and 89.2% (85.0–93.4) in the loose tablets group (P = 0.3). There was a lower incidence of early vomiting in the group receiving the fixed combination.Conclusion  This new fixed combination of mefloquine and artesunate was efficacious, well tolerated and convenient to administer.Keywords  artemisinin , fixed combination , malaria , mefloquine

Original publication

DOI

10.1111/j.1365-3156.2006.01724.x

Type

Journal article

Journal

Tropical Medicine & International Health

Publisher

Wiley

Publication Date

11/2006

Volume

11

Pages

1653 - 1660